Passed away [death].Case (b)(6) 2018 is a serious spontaneous case received from a consumer's spouse via a regulatory authority in the united states.This report concerns a male patient of unknown age who passed away during treatment with euflexxa (sodium hyaluronate) solution for injection, unknown concentration, unknown route of administration, 20 mg weekly for three weeks, for osteoarthritis from 2015 to an unknown stop date and in 2017 to an unknown stop date.A call was received from the patient's wife advising that her husband passed away on an unknown date in 2018.The patient died in 2018 due to unknown reason.Action taken with euflexxa was not applicable.At the time of this report, the outcome of death was fatal.Concomitant medication was not reported.All events in the case were reported as serious.At the time of reporting the case outcome was fatal.Overall listedness (core label) is unlisted.Reporter causality: related.Company causality: unassessable.Other case number= mw5077708.This ae occurred in the us and concerns the medical device euflexxa.Please report to your local health authority if required by local law.This ae is not reportable in eu because it did not occur in a eu + efta country and did not result in a corrective action by the manufacturer no corrective action was done by the manufacturer or requested by regulators.
|